34 Multiple Myeloma Clinical Trials in Miami, FL (2026)

Q: How do I join a clinical trial in Miami?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Miami research site will contact you.

Recruiting Multiple Myeloma Studies in Miami

NCT05361694Recruiting

Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions

The key aim of the study is to define the two biologically and clinically distinct entities: progressive versus stable myeloma precursor conditions....

Miami, FL1,000 participantsUniversity of Miami

View Study Details

NCT05020236Recruiting

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

The purpose of this clinical trial is to (1) learn whether the BCMA-CD3 bispecific antibody elranatamab can provide more benefit to people with multiple myeloma compared to a combination therapy inclu...

Miami, FLPHASE3944 participantsPfizer

View Study Details

NCT05438043Recruiting

A Study of Daratumumab

The purpose of this study is to provide ongoing access to study treatments for participants with multiple myeloma or smoldering multiple myeloma benefiting from treatment in certain Janssen Research a...

Miami, FLPHASE3500 participantsJanssen Research & Development, LLC

View Study Details

NCT06615479Recruiting

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple My...

Miami, FLPHASE3440 participantsJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

View Study Details

NCT03761108Recruiting

Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

The main purpose of this study is to learn about the safety of linvoseltamab and to find out what is the best dose of linvoseltamab to give to patients with multiple myeloma and to look for any signs ...

Miami, FLPHASE1387 participantsRegeneron Pharmaceuticals

View Study Details

NCT05895786Recruiting

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

The purpose of the study is to understand how the study medicine PF-06823859 works in people with idiopathic inflammatory myopathies (DM and PM). These disorders cause inflammation that weakens the mu...

Miami, FLPHASE3318 participantsPfizer

View Study Details

NCT04973605Recruiting

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM)...

Miami, FLPHASE1246 participantsBeiGene

View Study Details

NCT06297226Recruiting

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma....

Miami, FLPHASE2230 participantsJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

View Study Details

NCT06810518Recruiting

ALPCO Calprotectin CLIA Assay - Measurement of Calprotectin Levels in Human Stool

The ALPCO Calprotectin CLIA is an in vitro diagnostic test intended to quantitatively measure concentrations of fecal calprotectin in human stool samples. Calprotectin is a protein biomarker of mucosa...

Miami, FL220 participantsAmerican Laboratory Products Company

View Study Details

NCT06920004Recruiting

A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

The main purpose of this study is to compare empasiprubart and IVIg for treating people with CIDP. This study consists of a Part A where participants will either receive empasiprubart and a placebo re...

Miami, FLPHASE3218 participantsargenx

View Study Details

NCT05862012Recruiting

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

This study is a first-in-human, Phase 1, open-label study that will evaluate safety and anti-myeloma activity of ISB 2001 in participants with relapsed/refractory multiple myeloma (R/R MM)....

Miami, FLPHASE1200 participantsIchnos Sciences SA

View Study Details

NCT05850234Recruiting

A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma

This trial is a phase 1b/2, open-label, multicenter study of GC012F (AZD0120), a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory Multiple Myeloma....

Miami, FLPHASE1182 participantsAstraZeneca

View Study Details

NCT07032662Recruiting

IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

This is a Phase 2b study to evaluate the efficacy and safety of IMVT-1402 in adults with CIDP....

Miami, FLPHASE2162 participantsImmunovant Sciences GmbH

View Study Details

NCT07091630Recruiting

A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

The main purpose of this study is to demonstrate the efficacy and safety of empasiprubart in adults with CIDP. The study consists of a part A where participants will either receive empasiprubart or pl...

Miami, FLPHASE3160 participantsargenx

View Study Details

NCT07113522Recruiting

A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

This is a Phase 2, multicenter, platform study in adult participants with IBD (moderately to severely active Crohn's Disease or Ulcerative Colitis). The primary goal of this study is to assess the saf...

Miami, FLPHASE2140 participantsMirador Therapeutics, Inc.

View Study Details

NCT07190196Recruiting

A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease

This is a Phase 3, parallel group, 2-arm, randomized, double blind, placebo-controlled, 52-week treatment study to assess the efficacy and safety of rilzabrutinib as a treatment for adult patients wit...

Miami, FLPHASE3124 participantsSanofi

View Study Details

NCT07446777Recruiting

FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease

The purpose of this study is to find out whether a dietary approach that includes prolonged overnight fasting, guided by a Mediterranean-style eating pattern, is feasible for patients with myeloma pre...

Miami, FLNA120 participantsUniversity of Miami

View Study Details

NCT06997081Recruiting

ERd Combination Treatment in Newly Diagnosed Multiple Myeloma

The purpose of this study is to determine the effects that Elranatamab in combination with Lenalidomide and Dexamethasone has on participants that have been newly diagnosed with Multiple Myeloma....

Miami, FLPHASE2104 participantsUniversity of Miami

View Study Details

NCT02323399Recruiting

Study to Determine the Pharmacokinetics and Pharmacodynamic Effects of Phenylephrine on BP Via IV

The primary objective of this study is to evaluate the dose effect of Phenylephrine Hydrochloride Injection on the treatment of clinically relevant decreased blood pressure in the pediatric population...

Miami, FLPHASE4100 participantsWest-Ward Pharmaceutical

View Study Details

NCT07086976Recruiting

A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia

This is a parallel-group, Phase 3, double-blind, 2-arm study to investigate the efficacy, safety, PK and PD of oral rilzabrutinib in achieving durable Hb response (DHR) compared with placebo in approx...

Miami, FLPHASE390 participantsSanofi

View Study Details

NCT06215118Recruiting

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

The main purpose of the study is to understand how safe and tolerable is elranatamab when given along with iberdomide. There are 2 parts to this study. Part 1 will look at how safe and tolerable is e...

Miami, FLPHASE187 participantsPfizer

View Study Details

NCT06057402Recruiting

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab...

Miami, FLPHASE480 participantsPfizer

View Study Details

NCT06721013Recruiting

A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia

The purpose of the phase 1 part of this study is to evaluate how well pirtobrutinib is tolerated and what side effects may occur. The phase 2 part of the study will further investigate efficacy and sa...

Miami, FLPHASE168 participantsEli Lilly and Company

View Study Details

NCT07280013Recruiting

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

The main purpose of the study is to understand the safety and tolerability of cemsidomide when given along with elranatamab in subjects with relapsed or refractory multiple myeloma. The first part of...

Miami, FLPHASE160 participantsC4 Therapeutics, Inc.

View Study Details

NCT05722418Recruiting

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to deter...

Miami, FLPHASE150 participantsCaribou Biosciences, Inc.

View Study Details

NCT06100237Recruiting

Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)

The purpose of this study is to see whether combination treatment of Teclistamab and Daratumumab (Tel-Dara) or combination Talquetamab and Daratumumab (Tal-Dara) will delay the onset of multiple myelo...

Miami, FLPHASE250 participantsCarl Ola Landgren, MD, PhD

View Study Details

NCT07540221Recruiting

A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

The main goal of the study is to find out whether XEMBIFY, given once a week under the skin, provides similar levels of immunoglobulin G in the blood over time as Gamunex-C, which is given into a vein...

Miami, FLPHASE340 participantsGrifols Therapeutics LLC

View Study Details

NCT07160205Recruiting

Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)

The goal of this clinical trial is to learn about how an umbilical cord lining-derived stem cell (ULSC) product performs when treating Dermatomyositis/Polymyositis (DM/PM), also known as idiopathic in...

Miami, FLPHASE240 participantsRestem, LLC.

View Study Details

NCT06798012Recruiting

A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

CIDP is an autoimmune disease. This means that the body's germ fighting (immune) system attacks itself. In CIDP, the immune system attacks the protective covering around the nerves called myelin. Over...

Miami, FLPHASE236 participantsTakeda

View Study Details

NCT05530421Recruiting

Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma

The purpose of this research is to determine whether the combination of selinexor, venetoclax, and dexamethasone therapy can increase anti-cancer effects in patients with translocation 11;14-positive ...

Miami, FLPHASE233 participantsUniversity of Miami

View Study Details

NCT06910124Recruiting

Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse

The purpose of this study is to determine whether giving linvoseltamab with lenalidomide during maintenance treatment to participants with multiple myeloma will: 1. Get rid of any residual multiple m...

Miami, FLPHASE232 participantsDickran Kazandjian, MD

View Study Details

NCT05896228Recruiting

Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

The investigators want to find out whether or not giving patients who have relapsed or refractory multiple myeloma (MM) the experimental medication combination iberdomide, carfilzomib, daratumumab, an...

Miami, FLPHASE230 participantsBenjamin T Diamond, MD

View Study Details

NCT06376526Recruiting

IMMUNOPLANT for Newly Diagnosed Multiple Myeloma

The purpose of this study is to determine whether Linvoseltamab therapy in patients with newly diagnosed multiple myeloma will convert the disease status from minimal residual disease (MRD)-positive t...

Miami, FLPHASE228 participantsDickran Kazandjian, MD

View Study Details

NCT07368972Recruiting

Study of DISC-0974-201 in Participants With IBD and Anemia

This is a Phase 2, multicenter, randomized, double-blind placebo-controlled study of DISC-0974 to evaluate safety, tolerability, and efficacy in participants with IBD and anemia of inflammation....

Miami, FLPHASE221 participantsDisc Medicine, Inc

View Study Details

About Multiple Myeloma Clinical Trials in Miami

Multiple myeloma is a cancer of plasma cells in the bone marrow that produce abnormal antibodies. It can cause bone damage, kidney problems, and immune deficiency. Treatments have advanced significantly with proteasome inhibitors, immunomodulatory drugs, and CAR-T cell therapy.

There are currently 34 multiple myeloma clinical trials recruiting participants in Miami, FL. These studies are seeking a combined 6,540 participants. Research is being sponsored by University of Miami, Pfizer, Janssen Research & Development, LLC and 21 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Multiple Myeloma Clinical Trials in Miami — FAQ

Are there multiple myeloma clinical trials in Miami?

Yes, there are 34 multiple myeloma clinical trials currently recruiting in Miami, FL. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Miami?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Miami research site will contact you about next steps.

Are clinical trials in Miami free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Miami studies also compensate for your time and travel.

What multiple myeloma treatments are being tested?

The 34 active trials in Miami are testing new therapies including novel drugs, biologics, and treatment approaches for multiple myeloma.

Data updated July 16, 2026 from ClinicalTrials.gov